Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA-CSF1R refers to short hairpin RNA (shRNA) constructs designed to silence the expression of the Colony Stimulating Factor-1 Receptor (CSF1R) through RNA interference (RNAi). In preclinical research, particularly in melanoma, shRNA-CSF1R is used to investigate the functional role of CSF1R signaling in tumor growth, invasiveness, and the acquisition of resistance to BRAF inhibitors. Experimental studies have demonstrated that stable knockdown of CSF1R in melanoma cell lines leads to inhibited cell growth, increased apoptosis, and reduced metastatic potential. This modality is primarily utilized as a research tool for target validation and to provide a preclinical rationale for the use of CSF1R small molecule inhibitors, such as pexidartinib (PLX3397), in clinical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shRNA-CSF1R.